Proteomics-Driven Risk Stratification in Stage III Colon Cancer: A Validated Prognostic Signature for Recurrence Prediction using three independent cohorts

Key Points

• The study aims to establish a validated six-protein risk-score for better prognosis in stage III colon cancer.
• Developed a six-protein risk-score based on proteomics data.
• Validated the risk-score using three independent cohorts.
• Assessed improvement in prognostic stratification beyond standard clinical factors.
• The six-protein risk-score significantly enhances recurrence prediction accuracy.
• Provides a robust framework for risk-adapted clinical investigation.
• Suggests the need for prospective trials to explore its impact on adjuvant therapy decisions.